Newswire (Published: Monday, October 30, 2017, Received: Thursday, October 26, 2017, 7:56:42 PM CDT)

Word Count: 472

Research Data from Memorial Sloan-Kettering Cancer Center Update Understanding of Prostate Cancer (Drug development for noncastrate prostate cancer in a changed therapeutic landscape)

By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting originating from New York City, New York, by NewsRx correspondents, research stated, "The unprecedented progress in the treatment of metastatic castration-resistant prostate cancer is only beginning to be realized in patients with noncastrate disease. This slow progress in part reflects the use of trial objectives focused on time-to-event end points, such as time to metastasis and overall survival, which require long follow-up durations and large sample sizes, and has been further delayed by the use of approved therapies that are effective at the time of progression."

Our news editors obtained a quote from the research from Memorial Sloan-Kettering Cancer Center, "Our central hypotheses are that progress can be accelerated, and that outcomes can be improved by shifting trial objectives to response measures occurring early that solely reflect the effects of the treatment. To test these hypotheses, a continuously enrolling multi-arm, multi-stage randomized trial design, analogous to that used in the STAMPEDE trial, has been developed. Eligibility is focused on patients with incurable disease or those with a high risk of death with any form of monotherapy alone. The primary objective is to eliminate all disease using a multimodality treatment strategy. End points include pathological complete response and an undetectable level of serum prostate-specific antigen, with recovery of serum testosterone levels."

According to the news editors, the research concluded: "Both are binary, objective, and provide an early, quantitative indication of efficacy."

For more information on this research see: Drug development for noncastrate prostate cancer in a changed therapeutic landscape. Nature Reviews Clinical Oncology, 2017;():. (Nature Publishing Group - www.nature.com/; Nature Reviews Clinical Oncology - www.nature.com/nrclinonc/)

The news editors report that additional information may be obtained by contacting M.Y. Teo, Genitourinary Oncology Service, Dept. of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, United States. Additional authors for this research include M.J. O'Shaughnessy, S.M. McBride, H.A. Vargas and H.I Scher (see also Oncology - Prostate Cancer).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1038/nrclinonc.2017.160. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Oncology, New York City, United States, Article Review, Prostate Cancer, Drug Development, Drugs and Therapies, Prostatic Neoplasms, Risk and Prevention, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Companies

Memorial Sloan-Kettering Cancer Center

Places

Central America
North America
United States
Americas
New York
New York City

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research
      Medical and Pharmaceutical Regulation
            Drug and Device Approval Process
      Treatments and Therapies
            Medicinal Drugs